Identification of a novel merozoite surface antigen of Plasmodium vivax, PvMSA180

Malaria Journal

Table 1 Rate of seropositivity to the four domains of PvMAS180 of vivax-infected patients and naïve controls

Domains	No. of patient samples (n)			Normalized MFI^b	95% CI^d	No. of healthy samples (n)			Normalized MFI^b	95% CI^d	p value^e
Domains	Positive	Negative	Total (%)^a	Normalized MFI^b	95% CI^d	Positive	Negative	Total (%)^c	Normalized MFI^b	95% CI^d	p value^e
I	32	40	72 (44.4)	1.02	33.5–55.9	1	23	(22) 95.8	0.61	79.8–99.3	p < 0.0001
II	12	60	72 (16.7)	0.79	9.8–26.9	1	23	(22) 95.8	0.64	79.8–99.3	p < 0.01
III	29	43	72 (40.3)	1.02	29.7–51.8	1	23	(22) 95.8	0.70	79.8–99.3	p < 0.0001
IV	30	42	72 (41.7)	0.98	30.9–53.2	0	24	(24) 100	0.64	86.2–100	p < 0.0001

^aSeropositivity rate: percentage of positive malaria-patient samples
^bNormalized MFI: mean fluorescence intensities were divided by the cut-off value +2 standard deviations above the mean fluorescence intensity of the malaria-naïve samples
^cSero negative rate: percentage of malaria-naïve samples
^dConfidence intervals
^eDifference in the total IgG prevalence for each antigen between vivax patients and healthy individuals was calculated by the Student’s t-test. A value of P < 0.05 was considered statistically significant

ISSN: 1475-2875